Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium

PURPOSE: Lenalidomide is an immunomodulatory agent with therapeutic activity in chronic lymphocytic leukemia (CLL). In preclinical models, lenalidomide acted synergistically with rituximab. The CLL Research Consortium initiated a phase II study to evaluate this combination in treatment-naive patient...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: James, Danelle F., Werner, Lillian, Brown, Jennifer R., Wierda, William G., Barrientos, Jacqueline C., Castro, Januario E., Greaves, Andrew, Johnson, Amy J., Rassenti, Laura Z., Rai, Kanti R., Neuberg, Donna, Kipps, Thomas J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2014
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4067945/
https://ncbi.nlm.nih.gov/pubmed/24868031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.5890
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller